Found 165 cancer-center trials
A listing of cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
EA5221: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
This study aims to provide much-needed data regarding how to optimally treat vulnerable older adults with metastatic NSCLC.
UPCC 25223: A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants with Advanced/Recurrent HEpatocellular CarciNomA
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional Recurrent Head and Neck Squamous Cell Carcinoma
Phase 3
This is a Phase 3, randomized, double-arm, open-label trial of ASP-1929 photoimmunotherapy (ASP-1929 PIT) versus physician's choice standard of care (SOC) for the treatment of locoregional, recurrent head and neck squamous cell carcinoma (HNSCC) in patients who have failed or progressed on or after at least two lines of therapy, …
Expanded Access Protocol (Eap) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming
This study is designed to provide patients access to their nonconforming ide-cel as a treatment option for their disease. The study will evaluate the safety and effectiveness of this therapy through the collection of information. You may or may not receive direct medical benefit from participating in this study. The …
Observation of Residual Cancer With Liquid Biopsy Evaluation (ORACLE)
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and …
